Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 16/20 | 0.42 |
| ▸ | TNF | P01375 | 2/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31404965 | 0.86 | MRGPRX4 (0.42) | NOTUMALDH1A1MRGPRX4 | |
| SCHEMBL31405061 | 0.81 | IL1B (0.45) | IL1BTNFNLRP3 | |
| SCHEMBL31405044 | 0.80 | IL1B (0.40) | IL1BTNFNLRP3 | |
| SCHEMBL31404979 | 0.79 | IL1B (0.58) | IL1BTNFNLRP3 | |
| SCHEMBL31405016 | 0.79 | IL1B (0.40) | IL1BTNFNLRP3 | |
| SCHEMBL31624742 | 0.77 | NFKB1 (0.37) | NOTUMALDH1A1L3MBTL1MRGPRX4 | |
| SCHEMBL31405075 | 0.76 | IL1B (0.38) | IL1BTNFNLRP3 | |
| SCHEMBL30375350 | 0.74 | IL1B (0.35) | IL1BTNFNLRP3ALDH1A1L3MBTL1 | |
| SCHEMBL26093443 | 0.74 | ALOX5AP (0.36) | IL1BTNFNLRP3L3MBTL1 | |
| SCHEMBL26093672 | 0.74 | IL1B (0.35) | IL1BTNFNLRP3ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NOD1 | IL1B 1/4885TNF 53/4885NLRP3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.